SCHEMBL3857434

SCHEMBL3857434

NC(=O)OC1(Cc2ccccc2)CCC(C=O)(c2ccccc2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSK P43235 6/20 0.42
▸ CTSL P07711 4/20 0.42
▸ CTSB P07858 3/20 0.42
▸ LMNA P02545 1/20 0.36
▸ MAOA P21397 1/20 0.35
▸ MAOB P27338 1/20 0.35
▸ CTSS P25774 1/20 0.34
▸ OPRL1 P41146 3/20 0.33
▸ SLC1A3 P43003 2/20 0.32
▸ SLC1A2 P43004 2/20 0.32
▸ SLC1A1 P43005 2/20 0.32
▸ MEN1 O00255 2/20 0.32
▸ KMT2A Q03164 2/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ CYP2D6 P10635 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32
▸ CYP2C19 P33261 1/20 0.32
▸ ATM Q13315 2/20 0.32
▸ OPRM1 P35372 1/20 0.31
▸ OPRK1 P41145 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28951054 0.80 CTSK (0.49) CTSKCTSLCTSBLMNAMAOA
SCHEMBL7531427 0.79 CTSK (0.50) CTSKCTSLCTSBLMNAMAOA
SCHEMBL3864730 0.78 OPRM1 (0.46) OPRL1MEN1KMT2AOPRM1
SCHEMBL1725213 0.76 LMNA (0.41) CTSKCTSLCTSBLMNAMAOA
SCHEMBL28607722 0.74 LMNA (0.39) CTSKCTSLCTSBLMNAMAOA
SCHEMBL568885 0.72 MEN1 (0.41) MAOAMAOBOPRL1MEN1KMT2A
Hydrochloric Acid SCHEMBL28581691 0.71 MEN1 (0.40) MAOAMAOBOPRL1MEN1KMT2A
SCHEMBL27699361 0.70 CTSK (0.51) CTSKCTSLCTSBMAOAMAOB
SCHEMBL1881050 0.69 CTSK (0.43) CTSKCTSLCTSBLMNAMAOA
SCHEMBL28280874 0.69 CTSL (0.34) CTSKCTSLCTSBLMNAMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7589207-B2 Cyclohexyl compounds as CCR5 antagonists SMITHKLINE BEECHAM CORPORATION (US) 2009-09-15 — — US disclosed
EP-1569647-B1 CYCLOHEXYL COMPOUNDS AS CCR5 ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2008-08-20 — — EP disclosed
US-20060122166-A1 Cyclohexyl compounds as ccr5 antagonists SMITHKLINE BEECHAM CORPORATION 2006-06-08 — — US disclosed
EP-1569647-A2 CYCLOHEXYL COMPOUNDS AS CCR5 ANTAGONISTS SmithKline Beecham Corporation (US) 2005-09-07 — — EP disclosed
WO-2004054581-A2 CYCLOHEXYL COMPOUNDS AS CCR5 ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2004-07-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122166-A1 Cyclohexyl compounds as ccr5 antagonists CCR5, CCR1, CCR3 CTSK 1838/4885CTSL 498/4885CTSB 1532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback